Pipeline Digest Meets Specialty Drug Market Needs

EY Announces Dea Belazi of AscellaHealth as an Entrepreneur Of The Year 2023 National Finalist

PHL Inno - 5 Philadelphia-area companies make Deloitte's 2023 list of 500 fastest-growing tech firms

AscellaHealth Ranked Number 231 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Would Proposed Changes on Interchangeability Diminish Designation?

Ensuring Timely, Secure Delivery of Therapies for Rare Diseases

AscellaHealth Earns Merit-Based Philadelphia100 Award for Fourth Consecutive Year, Ranks #10 Among Fastest Growing, Private Companies in Philadelphia Region

AscellaHealth Assesses New, Anticipated Specialty Treatments

AscellaHealth President and CEO Dea Belazi Delivers Impactful Discussion at 2023 SIIA Annual Meeting: Specialty Pharmaceuticals and their Impact on Self-Insured Employers

AscellaHealth Named 2023 Best Global Specialty Pharmacy & Healthcare Services Organisation

AscellaHealth Earns Number One Spot for Fastest Growing Private Company and Number Two Spot on Philadelphia Business Journal “Soaring 76” Overall List of Fastest-Growing Companies

AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies

FDA Broadens Lonsurf Use in Colorectal Cancer

Now That Humira Biosimilars Have Launched, What Are Lessons Learned for Stelara Biosimilars?

Newer Drugs for ALL Are Hitting the U.S. Market, Potentially Filling Unmet Need

For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73 Percent

AscellaHealth: Providing a Rare and Special Perspective

AscellaHealth Releases Inaugural Specialty & Rare Pipeline Digest™: Includes FDA Approval Status for Specialty Drug Product Launches and Cell & Gene Therapies

NeuroSolv Therapeutics LLC Advances Spinal Cord Injury Treatment with Development of Perineline™ and Support from AscellaHealth LLC, a Global Healthcare & Specialty Pharmacy Solutions Company

Announcing the recipients of the 2023 Philadelphia Titan 100–Bill Oldham

Announcing the recipients of the 2023 Philadelphia Titan 100

Ahead of Influx of Humira Biosimilars, One Manufacturer Reveals ‘Aggressive’ Pricing Strategy

AscellaHealth Recognized Among Philadelphia Business Journal’s 2023 Best Places to Work

EY Announces Dea Belazi, CEO and President, AscellaHealth, as an Entrepreneur Of The Year 2023 Greater Philadelphia Award Winner

Slew of Adalimumab Biosimilars Are Expected in July

Coherus Reveals New Pricing Strategy for Its Humira Biosimilar

From international expansion to IPOs, this year's PACT Enterprise Award winners have big plans

AscellaHealth Recognized at 2023 PACT Enterprise Awards

Patients Often Lose in the Battle between Pharma and PBMs

AscellaHealth Captures Two Stevie Awards, Recognized as Fastest Growing Company and Marketing Department of the Year by 2023 American Business Awards

AscellaHealth Expands Worldwide Market Position, Unifies Solutions Under One Global Brand, Brings A Rare and Special Perspective to the Industry

Factors for Ensuring a Successful Launch and Market Access for Specialty Drugs and Novel Cell or Gene Therapies

EY Announces Dea Belazi, CEO and President, AscellaHealth, Entrepreneur Of The Year 2023 Greater Philadelphia Award Finalist

Critical Success Factors for Commercializing Specialty Drugs, Cell and Gene Therapies

Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs

AscellaHealth Recognized for Two Consecutive Years as One of “Americas' Fastest Growing Companies” by The Financial Times

AscellaHealth is 1 of 26 Philadelphia-area firms on Inc.’s List of Fastest-Growing Northeast Companies

AscellaHealth Ranks No. 48 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies

AscellaHealth Launches Biopharmaceutical Educational Podcast Series

Specialty Drug Tiering, Indication Expansions, IRA Are Some Issues to Watch

Humira Is Not Only Specialty Drug With Anticipated Biosimilars

Expect Rare Disease, Cancer, Immunology Drugs to Have Big Impact

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends

FDA Approved Four New Gene Therapies, Other Novel Agents in 2022

2022 Saw Continued Approvals, Uptake of Biosimilars

Specialty Pharmacy Trends to Watch in 2023

Seven Specialty Pharmacy Trends to Watch in 2023

Potential of Gene and Cell Therapies for Patients with Rare/Orphan Diseases, Ensuring Access to Treatment

PARP Inhibitors’ Data on Later Line Use in Ovarian Cancer Prompts Indication Withdrawals

AscellaHealth is One of Four Philadelphia-area companies which rank among Deloitte's 500 fastest-growing tech firms

AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

AscellaHealth - A Global Partner in Specialty Pharmacy Services for Life Sciences

Meeting the needs of rare disease patients: Improved access to specialty pharmaceuticals, gene and cell therapies

AscellaHealth Earns Merit-Based Philadelphia100 Award for Third Consecutive Year, Ranks Among Fastest Growing, Private Companies in Philadelphia Region

AscellaHealth Earns Spot on Philadelphia Business Journal “Soaring 76” List of Fastest-Growing Companies

AscellaHealth Named National Association of Specialty Pharmacy [NASP] Strategic Channel Partner of the Year

Survey Finds That Payers Are Covering Sequential Use of SMA Agents

AscellaHealth and Optime Care Collaborate with National Association of Specialty Pharmacy, Releases Podcast Series on Rare Disease Patient Journey

Deploying Next-Generation Technologies to Optimize Patient Care

AscellaHealth Family of Companies is Founding Sponsor of Inaugural Gene Therapy and Specialty Pharmacy Awareness Month, September 2022

AscellaHealth Named Philadelphia Business Journal PHL Inno 2022 Fire Award Honoree

AscellaHealth Achieves Favorable Ranking Among Prestigious 2022 Inc. Magazine’s 5000 Honorees: The Most Successful Companies in America For Second Consecutive Year

Terebellum, Global Healthcare and Specialty Pharmacy Solutions Company, Hosts Strategic Sessions to Architect 2023 International Pharmaceutical Partnerships and Management Training Programs

AscellaHealth and Dea Belazi honored in 2022 Fire Awards

Potential Expansion of Treatment Options for Breast Cancer

U.S. Sees First Ophthalmologic Biosimilar Launch in Crowded, High-Cost Space

Dea Belazi Named 2022 Titan 100 Award, Recognizing Philadelphia’s Top 100 CEO’s & C-level Executives

Cushing’s Syndrome

AscellaHealth Family of Companies Expands Subsidiary Terebellum’s Operations into Germany and United Kingdom, Adds New Executive Positions

Carvykti Approval Brings Second CAR-T to Multiple Myeloma Treatment

Ernst & Young Names Dea Belazi, CEO and President, AscellaHealth, Entrepreneur Of The Year 2022 Greater Philadelphia Award Finalist

AscellaHealth Awarded as One of The Financial Times’ “Americas' Fastest Growing Companies 2022” For Contribution to North and South America’s Economic Growth

AscellaHealth: Stalwarts of Specialty Pharmacy

AscellaHealth Earns Stevie Award, Named Gold Winner as Small Company of the Year for Pharmaceuticals by 2022 American Business Awards

The AscellaHealth Family of Companies Expands Executive Team Leadership for Ongoing Support of Strategic Business Initiatives and Accelerated Growth

AscellaHealth Launches Family of Companies, Expands Specialty Pharmacy Services and Capabilities to Serve Patients, Payers, Pharmaceutical Manufacturers and Providers

Success with SP Solutions

AscellaHealth’s Hub Solutions for Life Sciences Ensures Specialty Product Access and Market Entry, Optimizes Outcomes for Rare Disease Patients

Ask an Adviser: How can we cut specialty pharmacy costs?

Innovative Patient-First Approach Enhances Patient Journey, Mitigates Rising Costs for Rare Disease Drugs

AscellaHealth Hosts Specialty Pharmacy Carve-Out Webinar, Supports Self-Insured Employers and Plan Sponsors with Strategies to Manage Specialty Medical Benefit Rx Costs

With New Data, Oncopeptides Rescinds Pepaxto Withdrawal

Drug Pricing Remains Hot Topic, but Legislation Addressing It Has Stalled

Biosimilar Approvals Are Expected to Undergo Upward Trend in 2022

2022 Outlook: Notable FDA Approvals, Payer Strategies Are Specialty Trends

Optime Care Collaborates with National Association of Specialty Pharmacy, Develops Podcast on Patient Journey Across Specialty Pharmacy & Healthcare

AscellaHealth Enhances Site of Care Optimization, Awards Leading Pharmacies, Including Walmart, Preferred Status for Home Infusion Pharmacy Network

CMS Proposed NCD Will Provide Limited Medicare Coverage of Aduhelm, Other Similar Therapies

AscellaHealth Designates Preferred Status to Leading Pharmacies for Home Infusion Pharmacy Network, Enhances Site of Care Optimization

Specialty Pharmacy, Home Infusion Spaces Saw Myriad 2021 Changes

Notable 2021 Approvals Included Oncolytics, Interchangeables

Medicare Plans to Cover Aduhelm but With Certain Restrictions

AscellaHealth Awards Walmart Preferred Status for Home Infusion Pharmacy Network

Looking Forward to 2022, COVID-19 Will Continue to Impact Pharma in Myriad Ways

Innovative New Drugs, Collaborative Efforts, Digital Health Care Deals Were Among 2021 Trends

AscellaHealth Launches Expanded Website: User-Friendly Content on Global Specialty Pharmacy and Healthcare Services for Patients, Payers, Life Sciences and Providers

AscellaHealth Ranked Number 299 Fastest Growing Company in North America on the 2021 Deloitte Technology Fast 500™

AscellaHealth Forges Strategic Alliance with Optime Care

Dea Belazi’s blog on how technology advancements impact patient care

Daratumumab-RVd Demonstrates Clinical Benefits For Certain Patients With Multiple Myeloma